The role of biopsies in the treatment of colitis

Scoring of disease activity

Rish Pai, Karel Geboes

Research output: Chapter in Book/Report/Conference proceedingChapter

Abstract

The development of new medications leads to a better disease control and clinical remission. Many clinical trials are usually needed before a new therapy can be released. The aim of clinical trials is to show efficacy and safety of the drug by defining different endpoints such as clinical and endoscopic remission and by registration of adverse events. Histology is one of the elements used in clinical trials for the assessment of the efficacy of a drug, most often as a secondary endpoint. For this purpose, scoring systems for both ulcerative colitis (UC) and Crohn's disease (CD) have been developed for the measurement of disease activity. They usually rely on a combination of histological features. While they are not designed for routine practice, the underlying concepts may be useful in daily practice as numerous recent studies have shown the power of histologic disease activity to predict relapse and long-term outcomes.

Original languageEnglish (US)
Title of host publicationColitis
Subtitle of host publicationA Practical Approach to Colon and Ileum Biopsy Interpretation
PublisherSpringer International Publishing
Pages243-250
Number of pages8
ISBN (Electronic)9783319895031
ISBN (Print)9783319895024
DOIs
StatePublished - Jun 13 2018

Fingerprint

Colitis
Clinical Trials
Biopsy
Ulcerative Colitis
Crohn Disease
Pharmaceutical Preparations
Histology
Therapeutics
Safety
Recurrence

Keywords

  • Clinical trials
  • Disease activity
  • IBD
  • Mucosal healing
  • Score

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Pai, R., & Geboes, K. (2018). The role of biopsies in the treatment of colitis: Scoring of disease activity. In Colitis: A Practical Approach to Colon and Ileum Biopsy Interpretation (pp. 243-250). Springer International Publishing. https://doi.org/10.1007/978-3-319-89503-1_18

The role of biopsies in the treatment of colitis : Scoring of disease activity. / Pai, Rish; Geboes, Karel.

Colitis: A Practical Approach to Colon and Ileum Biopsy Interpretation. Springer International Publishing, 2018. p. 243-250.

Research output: Chapter in Book/Report/Conference proceedingChapter

Pai, R & Geboes, K 2018, The role of biopsies in the treatment of colitis: Scoring of disease activity. in Colitis: A Practical Approach to Colon and Ileum Biopsy Interpretation. Springer International Publishing, pp. 243-250. https://doi.org/10.1007/978-3-319-89503-1_18
Pai R, Geboes K. The role of biopsies in the treatment of colitis: Scoring of disease activity. In Colitis: A Practical Approach to Colon and Ileum Biopsy Interpretation. Springer International Publishing. 2018. p. 243-250 https://doi.org/10.1007/978-3-319-89503-1_18
Pai, Rish ; Geboes, Karel. / The role of biopsies in the treatment of colitis : Scoring of disease activity. Colitis: A Practical Approach to Colon and Ileum Biopsy Interpretation. Springer International Publishing, 2018. pp. 243-250
@inbook{d28ff8429f8a484bab9c66b878545d47,
title = "The role of biopsies in the treatment of colitis: Scoring of disease activity",
abstract = "The development of new medications leads to a better disease control and clinical remission. Many clinical trials are usually needed before a new therapy can be released. The aim of clinical trials is to show efficacy and safety of the drug by defining different endpoints such as clinical and endoscopic remission and by registration of adverse events. Histology is one of the elements used in clinical trials for the assessment of the efficacy of a drug, most often as a secondary endpoint. For this purpose, scoring systems for both ulcerative colitis (UC) and Crohn's disease (CD) have been developed for the measurement of disease activity. They usually rely on a combination of histological features. While they are not designed for routine practice, the underlying concepts may be useful in daily practice as numerous recent studies have shown the power of histologic disease activity to predict relapse and long-term outcomes.",
keywords = "Clinical trials, Disease activity, IBD, Mucosal healing, Score",
author = "Rish Pai and Karel Geboes",
year = "2018",
month = "6",
day = "13",
doi = "10.1007/978-3-319-89503-1_18",
language = "English (US)",
isbn = "9783319895024",
pages = "243--250",
booktitle = "Colitis",
publisher = "Springer International Publishing",

}

TY - CHAP

T1 - The role of biopsies in the treatment of colitis

T2 - Scoring of disease activity

AU - Pai, Rish

AU - Geboes, Karel

PY - 2018/6/13

Y1 - 2018/6/13

N2 - The development of new medications leads to a better disease control and clinical remission. Many clinical trials are usually needed before a new therapy can be released. The aim of clinical trials is to show efficacy and safety of the drug by defining different endpoints such as clinical and endoscopic remission and by registration of adverse events. Histology is one of the elements used in clinical trials for the assessment of the efficacy of a drug, most often as a secondary endpoint. For this purpose, scoring systems for both ulcerative colitis (UC) and Crohn's disease (CD) have been developed for the measurement of disease activity. They usually rely on a combination of histological features. While they are not designed for routine practice, the underlying concepts may be useful in daily practice as numerous recent studies have shown the power of histologic disease activity to predict relapse and long-term outcomes.

AB - The development of new medications leads to a better disease control and clinical remission. Many clinical trials are usually needed before a new therapy can be released. The aim of clinical trials is to show efficacy and safety of the drug by defining different endpoints such as clinical and endoscopic remission and by registration of adverse events. Histology is one of the elements used in clinical trials for the assessment of the efficacy of a drug, most often as a secondary endpoint. For this purpose, scoring systems for both ulcerative colitis (UC) and Crohn's disease (CD) have been developed for the measurement of disease activity. They usually rely on a combination of histological features. While they are not designed for routine practice, the underlying concepts may be useful in daily practice as numerous recent studies have shown the power of histologic disease activity to predict relapse and long-term outcomes.

KW - Clinical trials

KW - Disease activity

KW - IBD

KW - Mucosal healing

KW - Score

UR - http://www.scopus.com/inward/record.url?scp=85053653282&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85053653282&partnerID=8YFLogxK

U2 - 10.1007/978-3-319-89503-1_18

DO - 10.1007/978-3-319-89503-1_18

M3 - Chapter

SN - 9783319895024

SP - 243

EP - 250

BT - Colitis

PB - Springer International Publishing

ER -